title: [Thrombocyte-vascular and sero-coagulation hemostasis, and blood lipids in the acute period of ischemic stroke].
abstract: The subjects of the study were 46 patients at the acute stage of a first or repeated ischemic stroke (IS). The study revealed prevalence of procoagulating and thrombocyte activity of hemostasis, pronounced deficiency of physiological anticoagulants, high activity of Willebrand factor, and dislipidemia in these patients. The results show that secondary IS prophylaxy require combined antiaggregant therapy or combined therapy including anticoagulants and antithrombocyte agents plus correction of dislipidemia.
authors.forename: A N
authors.initials: AN
authors.lastname: Iasamanova
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Martynov
authors.forename: N N
authors.initials: NN
authors.lastname: Sudmol
mesh_terms: D000208:Acute Disease; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D001777:Blood Coagulation / Q000502:physiology*; D002545:Brain Ischemia / Q000097:blood* / Q000209:etiology / Q000517:prevention & control; D018450:Disease Progression; D050171:Dyslipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy; D005500:Follow-Up Studies; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008055:Lipids / Q000097:blood*; D015539:Platelet Activation / Q000502:physiology*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010976:Platelet Count; D011379:Prognosis
chemical_list: D000925:Anticoagulants; D000960:Hypolipidemic Agents; D008055:Lipids; D010975:Platelet Aggregation Inhibitors